Immune checkpoint inhibitor-associated nephritis-treatment standard
Descripción general
Resumen del artículo
This review summarizes current knowledge and treatment approaches for immune checkpoint inhibitor (ICI)-associated acute kidney injury (AKI), a side effect of cancer immunotherapy. It focuses on acute tubulointerstitial nephritis (ATIN), the most common form of ICI-AKI, discussing diagnosis, treatment, and outcomes, emphasizing the need for more prospective studies.
Explícamelo como si tuviera cinco años
Some cancer drugs can cause kidney problems as a side effect. Doctors are figuring out how to diagnose and treat these problems, but more research is needed.
Posibles conflictos de intereses
One author (SMH) has received research funding from intramural and Mayo Clinic grants. No specific funding was disclosed for the preparation of this manuscript.
Limitaciones identificadas
Explicación de la calificación
This is a comprehensive review of an important topic in onco-nephrology. It summarizes the current understanding of ICI-AKI and highlights key areas for future research. While it relies on retrospective studies, this is a limitation of the current evidence base. The authors acknowledge this weakness and call for more prospective research. Potential COI noted but seems minimal.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →